comparemela.com

Latest Breaking News On - Castle biosciences chart - Page 1 : comparemela.com

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx-Melanoma Test Results

01.12.2023 - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the . Seite 1

TissueCypher Barrett s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett s Esophagus Seite 1

14.09.2023 - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of data demonstrating that the TissueCypher Barrett’s Esophagus test outperformed standard of care . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.